Systemic anti-inflammation by synthetic interleukin-1 blockers.
@article{Chiou1999SystemicAB,
title={Systemic anti-inflammation by synthetic interleukin-1 blockers.},
author={George C. Y. Chiou and S X Liu},
journal={Zhongguo yao li xue bao = Acta pharmacologica Sinica},
year={1999},
volume={20 5},
pages={
405-8
}
}AIM
To study the systemic anti-inflammatory actions of interleukin-1 (IL-1) blockers, OB-101 and OB-186.
METHODS
Prevention of palm swelling induced by carrageenin injection was used as an animal model of systemic anti-inflammation efficacy.
RESULTS
Both OB-101 and OB-186 (10-30 mg.kg-1) were approximately 10-30-fold more potent than aspirin (300 mg.kg-1) to inhibit carrageenin-induced systemic inflammation. The LD50 of OB-101 and OB-186 were at least 20 g.kg-1 i.g., indicating that they…
3 Citations
A phenolic acid phenethyl urea compound inhibits lipopolysaccharide-induced production of nitric oxide and pro-inflammatory cytokines in cell culture.
- BiologyInternational immunopharmacology
- 2010
Review: effects of nitric oxide on eye diseases and their treatment.
- Biology, MedicineJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
- 2001
Underproduction and overproduction of nitric oxide (NO) could lead to various eye diseases which could be corrected by providing NOS substrates or NO donors to lower the intraocular pressure, increase ocular blood flow, relax ciliary muscle, etc.
Nitric oxide and cyclic GMP-mediated protein secretion from cultured lacrimal gland acinar cells.
- Biology, ChemistryJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
- 2002
No donors and NOS substrates were able to stimulate protein release from RLG cells via activation of guanylate cyclase and c-GMP release, which was blocked by guanylated cyclase inhibitor, ODQ, indicating that NO donors andNOS substrate could be used for the treatment of dry eye syndrome.